Search Results - "Hyland, R.H"

Prevalence of infection with multiple strains of hepatitis C virus (HCV) in patients enrolled in HCV clinical trials by Welzel, T.M, Ryan, M, Hedskog, C, Bhardwaj, N, Hyland, R.H, Martin, R, Stamm, L.M, Brainard, D.M, Mo, H, Svarovskaia, E, Nahass, R.G, Schiff, E.R, Katlama, C

Get full text

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy by Grebely, J, Jacobson, I.M, Kayali, Z, Verna, E.C, Shiffman, M.L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, McHutchison, J.G, Pol, S, Chung, R.T, Bernstein, D.E, Dore, G

Get full text

O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE by Gane, E.J, Hyland, R.H, An, D, Pang, P.S, Symonds, W.T, Mchutchison, J.G, Stedman, C.A

Get full text

No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies by Wyles, D, Thompson, A, Lawitz, E, Willems, B, Gane, E.J, Svarovskaia, E, Dvory-Sobol, H, Martin, R, Camus, G, Doehle, B.P, Stamm, L.M, Hyland, R.H, Brainard, D.M, Mo, H.M, Asselah, T, Jacobson, I, Foster, G.R, Roberts, S

Get full text

No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies by Sarrazin, C, Cooper, C.L, Manns, M.P, Reddy, R.K, Kowdley, K, Dvory-Sobol, H, Svarovskia, E, Martin, R, Doehle, B.P, Camus, G, Stamm, L.M, Hyland, R.H, Brainard, D.M, Mo, H, Gordon, S.C, Bourlière, M, Zeuzem, S, Flamm, S.L

Get full text

LP03 : Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis by Gane, E.J, Hyland, R.H, Ying, Y, Svarovskaia, E, Stamm, L.M, Brainard, D.M, Subramanian, G.M, McHutchison, J.G, Schwabe, C

Get full text

Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated with Sofosbuvir/Velpatasvir+GS-9857 for 6 or 8 Weeks by Gane, E, Svarovskaia, E.S, Dvory-Sobol, H, Hyland, R.H, Stamm, L.M, Brainard, D.M, Miller, M.D, Mo, H, Schwabe, C, Stedman, C.A

Get full text

Long-Term Follow-Up of Patients with Chronic HCV Infection following Treatment with Direct Acting Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations and Clinical Outcomes by Lawitz, E.J, Ruane, P, Stedman, C, Foster, G, Hyland, R.H, Coogan, S, Moody, S, Dvory-Sobol, H, Knox, S.J, Brainard, D.M, Abergel, A, Agarwal, K, Younes, Z, Schwabe, C

Get full text

High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 with or without Ribavirin for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1 HCV Infection by Lawitz, E, Poordad, F, Wells, J, Hyland, R.H, Yang, Y, Dvory-Sobol, H, Stamm, L.M, Brainard, D.M, McHutchison, J.G, Landaverde, C, Gutierrez, J

Get full text

SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies by Roberts, S.K, Cooper, C.L, Lawitz, E, Reddy, K.R, Thompson, A.J, Zeuzem, S, Jacobson, I.M, Ruane, P, Hyland, R.H, Stamm, L.M, Han, L, Brainard, D.M, Bräu, N, Asselah, T, Willems, B.E, Flamm, S, Bourlière, M, Foster, G.R, Gane, E.J, Manns, M, Gordon, S.C, Kowdley, K

Get full text

The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis by Manns, M, Gane, E.J, Willems, B.E, Roberts, S.K, Flamm, S, Bourliére, M, Asselah, T, Alric, L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, Khalili, M, Foster, G.R, Gordon, S.C, Reddy, K.R, Zeuzem, S, Jacobson, I.M, Cooper, C.L, Thompson, A.J, Kowdley, K, Lawitz, E

Get full text

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY by Gane, E.J, Stedman, C.A, Hyland, R.H, Pang, P.S, Ding, X, Symonds, W.T, McHutchison, J.G

Get full text

P1242 RESISTANCE ANALYSIS OF HCV GENOTYPE 1 INFECTED PATIENTS TREATED WITH SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR THE NS5B NONNUCLEOSIDE INHIBITOR GS-9669: THE ELECTRON STUDY by Svarovskaia, E.S, Martin, R, Gontcharova, V, Hyland, R.H, Gane, E.J, Stedman, C.A, Symonds, W.T, Miller, M.D, Mo, H

Get full text

P0711 : Genome-wide association study of response to sofosbuvir-ribavirin treatment in GT2/3 HCV patients by Kleinstein, S.E, Urban, T.J, Long, N, Thompson, A, Gane, E.J, Zeuzem, S, Jiang, Z, Ge, D, Paulson, M.S, Hyland, R.H, Brainard, D.M, Gaggar, A, Mani Subramanian, G, McHutchison, J.G, Muir, A, Sulkowski, M, Lawitz, E, Goldstein, D.B

Get full text

1113 ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3 by Gane, E.J, Stedman, C.A, Hyland, R.H, Sorensen, R.D, Symonds, W.T, Hindes, R.G, Berrey, M.M

Get full text

842 SOFOSBUVIR SAFETY AND TOLERABILITY IN 741 PATIENTS TREATED FOR UP TO 24 WEEKS by Kowdley, K.V, Hassanein, T, Gane, E.J, Hyland, R.H, Ma, J, Symonds, W.T, Lalezari, J, Lawitz, E

Get full text

845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY by Lalezari, J.P, Nelson, D.R, Hyland, R.H, Lin, M, Rossi, S.J, Symonds, W.T, Rodriguez-Torres, M, Lawitz, E.J

Get full text

848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR by Lawitz, E, Gane, E.J, Lalezari, J, Hyland, R.H, Ma, J, Symonds, W.T, Hassanein, T, Kowdley, K.V

Get full text

P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL by Zeuzem, S, Dusheiko, G.M, Colombo, M, Flisiak, R, Hyland, R.H, Illeperuma, A, Brainard, D.M, Symonds, W.T, McHutchison, J.G, Weiland, O, Reesink, H.W, Brown, A, Pol, S, Hezode, C, Esteban, R

Get full text

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY by Kowdley, K.V, Stuart, G.C, Reddy, R.K, Rossaro, L, Bernstein, D.E, An, D, Svarovskaia, E.S, Hyland, R.H, Pang, P.S, Symonds, W.T, Mchutchison, J.G, Muir, A.J, Pockros, P.J, Pound, D, Fried, M.W

Get full text